Approximately 15-20% of breast cancers are human epidermal growth factor receptor 2 (HER2)-positive, which is associated with aggressive disease and poor prognosis [1] . Combining trastuzumab with adjuvant chemotherapy improves survival among patients with HER2-positive early breast cancer, reducing the risk of recurrence and death. However, up to one in four people (25%) treated with trastuzumab and chemotherapy eventually relapse [2][3][4], and new approaches are needed. Dual blockage with trastuzumab and pertuzumab is an innovative strategy to enhance the clinical effectiveness of either agent administered singly. In randomized studies in the neoadjuvant setting, trastuzumab and chemotherapy-containing regimens have improved pathological complete response (pCR) at the time of surgery, which appears to correlate with improved disease outcomes. Thus, pCR may be able to serve as a surrogate marker of clinical benefit [5][6][7].
Introduction
Approximately 15-20% of breast cancers are human epidermal growth factor receptor 2 (HER2)-positive, which is associated with aggressive disease and poor prognosis [1] . Combining trastuzumab with adjuvant chemotherapy improves survival among patients with HER2-positive early breast cancer, reducing the risk of recurrence and death. However, up to one in four people (25%) treated with trastuzumab and chemotherapy eventually relapse [2] [3] [4] , and new approaches are needed. Dual blockage with trastuzumab and pertuzumab is an innovative strategy to enhance the clinical effectiveness of either agent administered singly. In randomized studies in the neoadjuvant setting, trastuzumab and chemotherapy-containing regimens have improved pathological complete response (pCR) at the time of surgery, which appears to correlate with improved disease outcomes. Thus, pCR may be able to serve as a surrogate marker of clinical benefit [5] [6] [7] .
Moreover, the combination of pertuzumab plus trastuzumab plus docetaxel, when used as first-line treatment for HER2-positive metastatic breast cancer, significantly prolonged progression-free survival compared with placebo plus trastuzumab plus docetaxel, and improved overall survival by 15.7 months [8] . Pertuzumab, a novel monoclonal antibody that functions as an anti-HER2 agent by targeting the extracellular dimerization domain of the HER2 receptor, was the first drug to receive, on September 30, 2013, accelerated approval by the US Food and Drug Administration for use in neoadjuvant settings in locally advanced, inflammatory, or early-stage breast cancer (either greater than 2 cm in diameter or node positive) HER2-positive breast cancer, based on the results of two clinical trials [9, 10] . In the NeoSphere trial, pertuzumab and trastuzumab plus docetaxel significantly improved pCR compared with those in patients given trastuzumab with docetaxel or pertuzumab with docetaxel (45.8% vs 29% vs 24%, respectively; p=0.01) [9] . In the Tryphaena trial, patients were randomized to one of three regimens: 6 cycles of docetaxel, carboplatin, trastuzumab, and pertuzumab (DCTP); 3 cycles of FEC (5-fluorouracil, epirubicin, and cyclophosphamide), FEC followed by 3 cycles of docetaxel plus trastuzumab/pertuzumab (FEC → DTP); or 3 cycles of FEC followed by 3 cycles of docetaxel, all concurrently with trastuzumab/pertuzumab (FEC-TP → DTP), resulting in a pCR (breast) rate of 61.6%, 57.3%, and 66.2%, respectively [10] .
The recently released final results of the much anticipated APHINITY trial, which explored the benefit of dual HER2 blockade in the adjuvant setting, confirm the outcome achieved in this patient.
Case description
A 49-year-old female presented with a 1.8 cm lump in her upper external right breast. Swollen lymph nodes were also identified in the right axilla. The pathological diagnosis was grade 2 invasive lobular carcinoma (ILC) and a positive ipsilateral lymph node. The biological features were estrogen receptor (ER)-negative, progesterone receptor (PgR)-negative, HER2 2+ (FISH overexpressed) and Ki-67 index 39%. There was no evidence of systemic disease through computed tomography (CT) scan thorax-abdomen-pelvis and bone scintigraphy. The patient was finally diagnosed with primary T1N1M0 breast cancer and underwent conservative surgery and lymph node dissection of the axilla on July 3rd, 2012. The final pathological report showed a multifocal grade 3 ILC, with a bigger (2. ) along with trastuzumab 6 mg/kg and pertuzumab 420 mg/placebo q3w (trastuzumab 8 mg/kg and pertuzumab 840 mg loading dose). Mild toxicity was observed: grade 1 peripheral neuropathy and grade 1 diarrhea. There was no decrease in heart left ventricular ejection fraction. After chemotherapy, she received radiotherapy in February/March 2013 and had completed 52 weeks of treatment with trastuzumab and pertuzumab-placebo at time of reporting. Since then, the patient has been followed up, with no evidence of local or systemic relapse 5 years after the surgery.
Discussion
Up to 25% of patients with HER2-positive and nodepositive operable breast cancer will have a relapse within 10 years, despite the use of adjuvant chemotherapy and 1 year of adjuvant trastuzumab. This is still far from optimal, and new options and strategies are needed for our patients.
In this regard, the APHINITY trial explored the benefits of dual HER2 blockade in the adjuvant setting [11] . The recently-released much anticipated final results of APHIN-ITY confirm the outcome achieved in this patient. APHINITY (Adjuvant Pertuzumab and Herceptin IN Initial TherapY in Breast Cancer) is a phase 3, international, randomized, double-blind, placebo-controlled, two-arm study evaluating the efficacy and safety of pertuzumab plus trastuzumab and chemotherapy compared with trastuzumab and chemotherapy, as an adjuvant therapy in 4,805 patients after undergoing surgery for HER2-positive cancer (NCT01358877/BO25126/BIG 4-11) [11] . Patients received 1 year of chemotherapy and trastuzumab, plus either pertuzumab or placebo; chemotherapy comprised a number of standard anthracycline/ taxane sequences or a non-anthracycline (TCH) regimen. Radiotherapy and/or endocrine therapy could be initiated at the end of adjuvant chemotherapy. The primary efficacy endpoint of APHINITY is invasive disease-free survival (iDFS), with an expected 3-year iDFS rate of 89.2% and 91.8% (hazard ratio [HR] 0.75) in the placebo and pertuzumab arm, respectively. After a median follow-up of 45.4 months, analysis showed a 19% relative risk reduction in the pertuzumab arm (94.1% vs 93.2%; stratified HR 0.81; p=0.045) [11] . Approximately 62% of both groups were node positive. In a predefined subgroup analysis of patients by nodal status, there was a 23% reduction in relative risk among the patients treated with pertuzumab compared with placebo (92% vs 90.2%; unstratified HR 0.77; p=0.019). Correspondingly, in the approximately 36% of patients who were hormone-receptor-negative, pertuzumab was associated with a relative risk reduction of 24% versus placebo (3-year iDFS 92.8% vs 91.2%; unstratified HR 0.76; p=0.085).
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The Authors declare there are no conflicts of interest in relation to this article. [5, 6] . Adding a second drug to adjuvant trastuzumab has already been explored in 3 studies. In the ALTTO trial different strategies including lapatinib were compared with 1 year of trastuzumab. Without entering into detail in the clinical trial design, the study was negative for the primary endpoint, so lapatinib was unable to demonstrate any statistical significant benefit [7] . The Exte-NET study explored the role of neratinib, an irreversible tyrosine kinase small-molecule inhibitor against the HER kinase family, in the adjuvant setting [8] 
Commentary

Although the prognosis for both human epidermal growth factor receptor 2 (HER2)-positive early and metastatic breast cancer has changed dramatically with the introduction of anti-HER2 therapies, many patients still relapse and will ultimately die as a consequence of their disease [1-3]. In the adjuvant scenario, 1-year trastuzumab based-therapy is now considered the standard of care for the majority of patients, even with very small tumors, due to the aggressiveness of this disease. Although there have been several studies designed to improve 1-year trastuzumab-based therapy outcomes, statistically significant results were generally not observed. Longer duration of trastuzumab was explored in the HERA trial, which demonstrated that 2 years of trastuzumab was not better than 1 year [4]. Moreover, other trials have been designed to explore if lower cycles of trastuzumab could be non-inferior to the 1-year schedules. At the time being, none of the data support shorter courses, and 1 year of trastuzumab remains as the standard of care
